Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 135INDUSTRY 94NIH 10OTHER_GOV 2NETWORK 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Testicular Neoplasms 1Testicular Diseases 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Lymphoma, B-Cell 1Gonadal Disorders 1

Interventions

Cisplatin 48Capecitabine 41Gemcitabine 33apatinib 32Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Nivolumab 17pembrolizumab 16Surgical Procedures, Operative 16Exercise 16Metformin 15S 1 (combination) 14camrelizumab 13Radiation 13Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11Vinorelbine 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × avelumab × Clear all
NCT03244176 2024-07-30

AvR-CHOP

Austin Health

Phase EARLY_PHASE1 Active not recruiting
28 enrolled
Lymphoid

Lymphoma, B-Cell

NCT03403777 2019-03-05

Avelumab in Refractory Testicular Germ Cell Cancer.

National Cancer Institute, Slovakia

Phase 2 Completed
8 enrolled
Genitourinary

Gonadal Disorders, Neoplasms, Neoplasms, Germ Cell and Embryonal, Testicular Diseases, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡